Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

More documents

Recommendations

Info

5.10 Assessment and administration5.10.1 Introduction5.10.2 Recommendations for administration of nebulised antimicrobials5.11 Antibiotic choice and formulation5.12 Safety of long term inhaled antibiotics5.12.1 Increased bacterial resistance5.12.2 Intrinsically resistant bacteria5.12.3 Serum aminoglycoside concentrations5.12.4 Bronchoconstriction5.12.5 Pregnancy5.12.6 Nebuliser equipment as a source of bacterial contamination5.12.7 Other5.12.8 Recommendations to minimise systemic adverse effects5.12.9 Recommendations on nebuliser maintenance5.13 Environmental safety5.13.1 Introduction5.13.2 Recommendations on environmental safety5.14 Antibiotic delivery5.14.1 Antibiotic preparations5.14.2 Recommendations for reconstitution of nebulised antimicrobials5.15 Antibiotic doses5.16 Nebuliser/compressor systems for antibiotics5.16.1 Characteristics of available devices5.16.2 Recommendations for nebuliser devices5.17 Travel nebuliser/compressor systems5.18 References6. INTRAVENOUS ANTIBIOTICS6.1 Introduction6.2 Why treat?6.2.1 Early onset of infection and inflammation in CF6.2.2 Pseudomonas aeruginosa6.2.3 Evidence for the use of intravenous antibiotics6.3 Who should be treated?6.4 Which antibiotics should be used?6.4.1 General principles6.4.2 Some specific problems with P.aeruginosa6.4.2i Which antibiotic combination should be chosen?6.4.2ii Multiple antibiotic resistance6.4.2iii Sputum sensitivities may be discordant with the outcome of antibiotictreatment in the patient6.5 What dose, for how long, and in what setting should antibiotics be given?6.6 How can we minimise the cumulative side effects of treatment?6.7 Recommendations6.8 ReferencesCystic Fibrosis Trust ContentsMarch 2009
7. OTHER INFECTIONS7.1 Management of respiratory exacerbations in patients with Burkholderia cepacia complex7.1.1 Introduction7.1.2 Recommendations for the treatment of Burkholderia cepacia complex7.2 Respiratory infection with meticillin-resistant Staphylococcus aureus7.2.1 Introduction7.2.2 Treatment7.2.3 Recommendations – eradication and treatment of MRSA7.2.4 Recommendations – regimens for treating MRSA colonisation/infection of nonrespiratorysites7.3 Respiratory infection with Stenotrophomonas maltophilia7.3.1 Introduction7.3.2 Recommendations7.4 Respiratory infection with Achromobacter (Alcaligenes) xylosoxidans7.4.1 Introduction7.4.2 Recommendations7.5 Respiratory infection with Pandoraea sp.7.5.1 Introduction7.5.2 Recommendations7.6 Influenza A infection7.6.1 Introduction7.6.2 Recommendations7.7 Totally implantable intravenous access device (TIVAD) infections7.7.1 Introduction7.7.2 Recommendations7.8 Non-tuberculous mycobacteria7.8.1 Prevalence of non-tuberculous mycobacteria7.8.2 Clinical significance of non-tuberculous isolates in sputa from patients with cysticfibrosis7.8.3 Treatment7.8.4 Recommendations7.9 Aspergillus7.9.1 Prevalence and risk factors for allergic bronchopulmonary aspergillosis (ABPA)7.9.2 Diagnosis of ABPA7.9.3 Treatment of ABPA7.9.4 Recommendations for management of ABPA7.9.5 Invasive pulmonary aspergillosis, aspergillomas, and aspergillus bronchitis7.9.6 Recommendations for invasive pulmonary aspergillosis, aspergillomas, andaspergillus bronchitis7.9.7 Other fungi7.9.8 Recommendations for unusual fungal infection7.10 ReferencesCystic Fibrosis Trust ContentsMarch 2009
Page 3: 4. ORAL ANTIBIOTICS IN CYSTIC FIBRO
Page 7 and 8: GRADING SCHEME FOR LEVELS OF EVIDEN
Page 9 and 10: SUMMARY•All young children with c
Page 11: In 1989 the Copenhagen centre recom
Page 15 and 16: These bacteria can be harmless comm
Page 17 and 18: 2.7 Clinical relevance of in vitro
Page 19 and 20: 17. Macia MD, Blanquer D, Togores B
Page 21 and 22: 3.1 Introduction3. IDENTIFICATION O
Page 23 and 24: Table 2: Laboratory techniques and
Page 25 and 26: 20. Hoppe JE, Theurer MU, Stern M.
Page 27 and 28: 4.2.4 Recommendations for treatment
Page 29 and 30: 4.5 Use of oral antibiotics at time
Page 31 and 32: groups in terms of the chronic use
Page 33 and 34: 5.1 Introduction5. NEBULISED ANTIBI
Page 36 and 37: 5.5 Nebulised antibiotics to preven
Page 38 and 39: 5.10.2 Recommendations for administ
Page 40 and 41: • If a facemask is used the face
Page 42 and 43: 5.16 Nebuliser/compressor systems f
Page 44 and 45: 19. Ratjen F, Walter H, Haug M, Mei
Page 46 and 47: 69. Pitchford KC, Corey M, Highsmit
Page 48 and 49: outcome between active and placebo
Page 50 and 51: Drug Route Age/weight DoseFrequency
Page 52 and 53: much sooner. A minimum of 10-14 day
Page 54 and 55:
6.8 References1. Armstrong DS, Grim
Page 56 and 57:
7. OTHER INFECTIONS7.1 Management o
Page 58 and 59:
7.2 Respiratory infection with meti
Page 60 and 61:
Table 7.2 Published data on eradica
Page 62 and 63:
7.4.2 Recommendations• Given the
Page 64 and 65:
although not all authors have found
Page 66 and 67:
Table 7.3 Drugs for treatment of My
Page 68 and 69:
7.9.2 Diagnosis of ABPAThe Cystic F
Page 70 and 71:
• It is important to assess the c
Page 72 and 73:
12. Blackburn L, Brownlee K, Conway
Page 74 and 75:
57. Ballestero S, Virseda I, Escoba
Page 76 and 77:
107. Deerojanawong J, Sawyer SM, Fi
Page 78 and 79:
155. Stevens DA, Moss RB, Kurup VP,
Page 80 and 81:
8. PHARMACOPOEIAOriginally based on
Page 82 and 83:
8.3 Treatment of more severe exacer
Page 84 and 85:
Co-amoxiclav orallyAge Dose Frequen
Page 86 and 87:
Cefotaxime intravenouslyAge Dose Fr
Page 88 and 89:
8.7 Treatment of Pseudomonas aerugi
Page 90 and 91:
8.8.3 Other ß-lactam antibioticsTh
Page 92 and 93:
Amikacin intravenouslyAge Dose Freq
Page 94 and 95:
8.10 Chronic oral anti-pseudomonal
Page 96 and 97:
TemocillinAge Dose Frequency>12year
Page 98 and 99:
Liposomal Amphotericin (“Ambisome
Page 100 and 101:
9. ANTIBIOTIC-RELATED ALLERGIES AND
Page 102:
I N F O R M A T I O NCystic Fibrosi
show all

Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

Create successful ePaper yourself

Delete template?

Save as template?